Combination-Only Approvals as a Barrier to Affordable HIV Care

“Combination-only” drug approvals, in which new HIV medications are approved only as part of multi-drug combinations and not as standalone products, are keeping HIV treatment costs high by blocking generic competition and preventing cost-saving regimen changes. To expand affordable access to HIV care, the FDA should require that new drugs used in combinations also be approved as monotherapies